$DRRX News
Last published 1y ago
- 1y agoBHCDRRXBausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025ACCESS NewswireLAVAL, QC AND CUPERTINO, CA / ACCESS Newswire / August 26, 2025 / Bausch Health Companies Inc. , a global, diversified pharmaceutical company, and DURECT Corporation today announced that
- 1y agoDRRXDURECT Corporation Reports Second Quarter 2025 Financial Results and Provides Update on Proposed Acquisition by Bausch HealthPR NewswireDURECT Corporation (Nasdaq: DRRX) today announced financial results for the second quarter ended June 30, 2025 and provided an update on the...
- 1y agoBHCDRRXBausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver DiseaseACCESS NewswireDURECT's lead asset, Larsucosterol, is an epigenetic modulator with FDA Breakthrough Therapy DesignationPotential to be the first FDA-approved therapeutic option for the treatment of patients with alcoholic
- 1y agoBHCDRRXBausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver DiseasePR NewswireBausch Health Companies Inc. (NYSE: BHC) (TSX: BHC), a global, diversified pharmaceutical company, and DURECT Corporation (NASDAQ: DRRX) today...
- 1y agoDRRXDURECT Corporation Reports First Quarter 2025 Financial Results and Provides Business UpdatePR NewswireDURECT Corporation (Nasdaq: DRRX) today announced financial results for the first quarter ended March 31, 2025 and provided a business update. "Our...
- 1y agoDRRXDURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdatePR NewswireDURECT Corporation (Nasdaq: DRRX) today announced financial results for the fourth quarter and full year ended December 31, 2024 and provided a...
- 1y agoDRRXDURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business UpdatePR NewswireDURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated ...
- 1y agoDRRXDURECT Corporation to Present at Oppenheimer 35th Annual Healthcare Life Sciences ConferencePR NewswireDURECT Corporation (Nasdaq: DRRX) today announced that James E. Brown, President and Chief Executive Officer, will present at the Oppenheimer 35th...
- 1y agoDRRXDURECT Corporation Announces Publication of Larsucosterol Phase 2b Results in NEJM EvidencePR NewswireDURECT Corporation (Nasdaq: DRRX) today announced the publication of a peer-reviewed article on the AHFIRM trial data in NEJM Evidence. The full...
- 1y agoDRRXDURECT Corporation Announces Sale of ALZET® Product Line to Lafayette Instrument Co. for $17.5 MillionPR NewswireDURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the...
- 1y agoDRRXDURECT Corporation (DRRX) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoDRRXDURECT Corporation Reports Third Quarter 2024 Financial Results and Provides Business UpdatePR NewswireDURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2024 and provided a business update. "We ...
- 2y agoDRRXDURECT Corporation to Announce Third Quarter 2024 Financial Results and Provide a Business UpdatePR NewswireDURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the...
- 2y agoDRRXDURECT Corporation to Present Data on Larsucosterol at The Liver Meeting 2024PR NewswireDURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the...
- 2y agoDRRXDURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-associated HepatitisPR NewswireDURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the...
- 2y agoDRRXDURECT Corporation to Present at the H.C. Wainwright Global Investment ConferencePR NewswireDURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the...
- 2y agoAVTXDRRXHALOMESO+1KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial OfficerBusiness WireKaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announces the appointment of Schond Greenway as Chief Financial Officer (CFO).
- 2y agoDRRXDURECT Corporation (DRRX) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoDRRXDURECT Corporation Reports Second Quarter 2024 Financial Results and Business UpdatePR NewswireDURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2024 and provided a business update. "Our...
- 2y agoDRRXDURECT Corporation to Announce Second Quarter 2024 Financial Results and Provide a Business UpdatePR NewswireDURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the...
- 2y agoDRRXDURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated HepatitisPR NewswireDURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the...
- 2y agoDRRXDURECT Corporation (DRRX) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoDRRXDURECT Corporation Reports First Quarter 2024 Financial Results and Business UpdatePR NewswireDURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, 2024 and provided a business update. "We are ...
- 2y agoDRRXDURECT Corporation to Announce First Quarter 2024 Financial Results and Provide a Business UpdatePR NewswireDURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the...
- 2y agoDRRXDURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated HepatitisPR NewswireDURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the...
- 2y agoDRRXDURECT Corporation (DRRX) Q4 2023 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoDRRXDURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdatePR NewswireDURECT Corporation (Nasdaq: DRRX) today announced financial results for the fourth quarter and year ended December 31, 2023 and provided a business...
- 2y agoDRRXDURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business UpdatePR NewswireDURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the...
- 2y agoDRRXDURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and CanadaPR NewswireDURECT Corporation (Nasdaq: DRRX), today announced that it has entered into a co-marketing and collaboration agreement with Charles River...
- 2y agoDRRXDURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferencePR NewswireDURECT Corporation (Nasdaq: DRRX) today announced that James E. Brown, President and Chief Executive Officer, will present at the Oppenheimer 34th...
- 2y agoDRRXDURECT Corporation Reports Third Quarter 2023 Financial Results and Business UpdatePR NewswireDURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2023 and provided a corporate update....
- 3y agoDRRXDURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business UpdatePR NewswireDURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the...
- 3y agoDRRXDURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on MortalityPR NewswireDURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the...
- 3y agoDRRXDURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated HepatitisPR NewswireCompany on track to report topline data from AHFIRM in Q4 2023 CUPERTINO, Calif., Sept. 7, 2023 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX), a late-stage biopharmaceutical company pioneering the development of
- 3y agoDRRXDURECT Corporation Announces Presentations in Upcoming Investor ConferencesPR NewswireCUPERTINO, Calif., Aug. 31, 2023 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel
- 3y agoDRRXDURECT Corporation Reports Second Quarter 2023 Financial Results and Business UpdatePR Newswire- Webcast of Earnings Call Today, August 9th at 4:30 p.m. ET - Topline data from AHFIRM trial expected in Q4 2023 CUPERTINO, Calif., Aug. 9, 2023 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced
- 3y agoDRRXDURECT Corporation Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesPR NewswireCUPERTINO, Calif., July 20, 2023 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) ("DURECT"), a biopharmaceutical company focused on developing its epigenetic regulator program for the treatment of acute organ
- 3y agoDRRXDURECT Completes Enrollment in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated HepatitisPR NewswireTopline data anticipated in Q4 2023 CUPERTINO, Calif., June 7, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company developing epigenetic therapies for the treatment of acute organ injuries
- 3y agoDRRXDURECT Corporation Reports First Quarter 2023 Financial Results and Business UpdatePR Newswire- Webcast of Earnings Call Today, May 8th at 4:30 p.m. ET - Topline data from AHFIRM trial expected in 2H 2023 CUPERTINO, Calif., May 8, 2023 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial
- 3y agoDRRXDURECT Corporation to Announce First Quarter 2023 Financial Results and Provide Business Update on May 8PR NewswireCUPERTINO, Calif., May 1, 2023 /PRNewswire/ --- DURECT Corporation (NASDAQ:DRRX) today announced that it will report its first quarter 2023 financial results and host a conference call after the market close on Monday,
- 3y agoDRRXDURECT Corporation to Participate in Fireside Chat at the H.C. Wainwright BioConnect Investor ConferencePR NewswireCUPERTINO, Calif., April 25, 2023 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced that Dr. James Brown, President and CEO, will participate in a fireside chat hosted by Ed Arce, Managing Director, Senior
- 3y agoDRRXDURECT Announces Peer-Reviewed Article Accepted for Publication with Additional Data from Previously Completed Phase 2a Study of Larsucosterol in Alcohol-Associated HepatitisPR NewswireData expands upon previously reported results, including individual patient data, additional liver biomarkers, and comparisons to matching arms from a contemporaneous study Company on track to report data from ongoing
- 3y agoDRRXDURECT Corporation Announces Appointment of Gail Maderis as Chair of the BoardPR NewswireCUPERTINO, Calif., March 21, 2023 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) announced today that Gail Maderis has assumed the role of Chair of the Board of DURECT effective March 17, 2023. Ms. Maderis succeeds
- 3y agoDRRXDURECT Corporation Fireside Chat at the Oppenheimer 33rd Annual Healthcare ConferencePR NewswireCUPERTINO, Calif., March 9, 2023 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced that Dr. James Brown, President and CEO and additional members of the management team will participate in a fireside chat
- 3y agoDRRXDURECT Corporation Reports Fourth Quarter and Full Year 2022 Financial Results and AHFIRM Trial UpdatePR Newswire- Webcast of Earnings Call Today, March 7th at 4:30 p.m. ET - Topline data from AHFIRM trial expected in 2023 CUPERTINO, Calif., March 7, 2023 /PRNewswire / -- DURECT Corporation (NASDAQ:DRRX) today announced financial
- 3y agoDRRXDURECT Corporation to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 7PR NewswireCUPERTINO, Calif., Feb. 28, 2023 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced that it will report its fourth quarter and full year 2022 financial results and host a conference call after the market
- 3y agoDRRXDURECT Corporation Announces $10 Million Registered Direct Offering of Common Stock and WarrantsPR NewswireCUPERTINO, Calif., Feb. 3, 2023 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) ("DURECT"), a biopharmaceutical company focused on developing its epigenetic regulator program for the treatment of acute organ
- 3y agoDRRXDURECT Announces 1-for-10 Reverse Stock SplitPR NewswireCUPERTINO, Calif., Nov. 28, 2022 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX), a biopharmaceutical company focused on developing epigenetic regulator programs for the treatment of acute organ injury and chronic liver
- 4y agoDRRXDURECT Corporation Reports Third Quarter 2022 Financial Results and Update of ProgramsPR Newswire- Webcast of Earnings Call Today, November 2nd at 4:30 p.m. ET - AHFIRM trial timeline continues to improve CUPERTINO, Calif., Nov. 2, 2022 /PRNewswire / -- DURECT Corporation (NASDAQ:DRRX) today announced financial
- 4y agoDRRXDURECT Corporation to Announce Third Quarter 2022 Financial Results and Provide Business Update on November 2PR NewswireCUPERTINO, Calif., Oct. 26, 2022 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced that it will report its third quarter 2022 financial results and host a conference call after the market close on